Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
While the rail & transport asset monitoring product is MNO’s core product currently, the fintec banking product still has potential for a future relaunch.
The main reason it was stopped was that a majority of SME customers in US were simply not using online banking yet. The pandemic has likely accelerated the adoption of online banking for small businesses and the product may become in demand sooner than expected. Interesting to note that MNO’s peers in this space such as 9SP (ASX) have had some success here and very strong share rises in recent weeks with a market cap many multiples of MNO’s
The chairman bought £35k’s worth of shares in the open market in March, a sign of confidence
I think they have a great strategy now, MNO’s flagship product is complemented by the latest data management capabilities and strong data integration experience, which gives them a big advantage over other products in the asset inspection industry.
Here are some direct questions that HRnetGroup have had to answer recently about it’s Staffline investment. (Q2, I-VI)
http://investor.hrnetgroup.com/newsroom/20200506_180911_CHZ_S4F2AAR77R15L0B6.1.pdf
some substantial updates due soon on audit, full results, banking facilities, liquidity. Good news here can send the price soaring. On the flip side got to watch out for any significant writedowns, exceptional charges or capital raising.
An update on trading is probably less significant at the moment than the above as we know recruitment has slowed substantially in recent months, question is how fast it will pick up
I think the pandemic has not really delayed projects as many rail companies have used the time to carry out maintenance, including rail infrastructure assessments. Australia has not seen a significant lockdown.
The move into new markets, particularly Americas is potentially very significant especially with the ageing US rail network. There are US plans to invest nearly $30 billion in passenger railroad Amtrak and rail infrastructure and some if this spend may well end up with MNO
GHIF has been with GDR since 2014, so a long-term loan provider and now to become a shareholder, I don’t think they will exit anytime soon.
Interesting to note the strike price for the loans converted:
a. Tranche 1, $2.0m plus deferred interest at 28.75p per share
b. Tranche 2, $6m plus deferred interest at 150.0p per share
I agree WG, there is likely to be an update about the ongoing projects. The Australian rail project should be well advanced now and the Japanese rail project will hopefully be at a stage where they expand the pilot.
What I’m also hoping for is a break into the Americas market (US/Canada), that would be significant.
Interesting to see Faron Pharma getting a grant from the Finland Government to manufacture more Interferon:
“This is a very important initiative backed by the Finnish Government. We have a good existing stock of IFN beta-1a, but given the on-going clinical trials (REMAP-CAP and The WHO's Solidarity Trial) and the potential for increasing future demand of IFN beta-1a for COVID-19 and other viral infections like influenza we need to begin up-scaling our manufacturing capacity."
Results due end of June, as there is no associated trading update with today’s rns, this probably means they are trading in-line upto 31 March. Will be Interesting to hear what contracts are in progress after this period end as that is where the opportunities from accelerated IT spend are coming from now
Perhaps some news will appear next week... if so, it could be an update on the Australian or Japanese railway projects or it could indeed be further new contract wins.